YS Biopharma’s PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study

By / 27/03/2023

YS Biopharma announced its positive interim Phase II safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine.